Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018081475) BROMODOMAIN AND EXTRA-TERMINAL PROTEIN INHIBITOR COMBINATION THERAPY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/081475 International Application No.: PCT/US2017/058614
Publication Date: 03.05.2018 International Filing Date: 26.10.2017
IPC:
A61K 31/47 (2006.01) ,A61K 31/337 (2006.01) ,A61K 31/495 (2006.01) ,A61K 38/07 (2006.01) ,A61K 38/15 (2006.01) ,C07D 211/22 (2006.01) ,C07D 217/24 (2006.01) ,C07D 471/04 (2006.01) ,C07D 487/04 (2006.01)
[IPC code unknown for A61K 31/47][IPC code unknown for A61K 31/337][IPC code unknown for A61K 31/495][IPC code unknown for A61K 38/07][IPC code unknown for A61K 38/15][IPC code unknown for C07D 211/22][IPC code unknown for C07D 217/24][IPC code unknown for C07D 471/04][IPC code unknown for C07D 487/04]
Applicants:
CELGENE QUANTICEL RESEARCH, INC. [US/US]; 9393 Towne Centre Drive San Diego, California 92129, US
Inventors:
CHO, Robert; US
STAFFORD, Jeffrey Alan; US
Agent:
SUNG, Lawrence M.; US
SYLVIA, Mary; US
Priority Data:
62/413,76327.10.2016US
62/560,84020.09.2017US
Title (EN) BROMODOMAIN AND EXTRA-TERMINAL PROTEIN INHIBITOR COMBINATION THERAPY
(FR) POLYTHÉRAPIE PAR INHIBITEUR DE PROTÉINE À BROMODOMAINE ET DOMAINE EXTRA-TERMINAL
Abstract:
(EN) The present disclosure relates generally to compositions and methods of treating neoplastic diseases or cancers, such as glioblastoma and non-Hodgkin's lymphomas, or other cancers in which the subject suffers from an advance solid tumor, comprising a combination of, or administering a combination of, a bromodomain and extra-terminal protein BET inhibitor and at least on echemotherapeutic agent, which does not inhibit BET directly. The BET inhibitor/chemotherapeutic agent combination, or combination therapy, can yield syngergistic effects, thereby increasing the effectiveness of the cancer treatment as compared with the administration of either the BET inhibitor or the chemotherapeutic agent alone.
(FR) La présente invention concerne d'une manière générale des compositions et des méthodes de traitement de maladies néoplasiques ou de cancers, tels que le glioblastome et les lymphomes non hodgkiniens, ou d'autres cancers dans lesquels le sujet souffre d'une tumeur solide avancée, comprenant une combinaison ou l'administration d'une combinaison d'un inhibiteur de protéine à bromodomaine et domaine extra-terminal (BET) et d'au moins un agent chimiothérapeutique qui n'inhibe pas directement la protéine BET. La combinaison inhibiteur de BET/agent chimiothérapeutique, ou la polythérapie, peut générer des effets synergiques, de manière à augmenter l'efficacité du traitement anticancéreux par comparaison à l’administration soit de l’inhibiteur de BET soit de l'agent chimiothérapeutique seul.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)